{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T05:54:01Z","timestamp":1770789241120,"version":"3.50.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The optimal neoadjuvant strategy for high-risk locally advanced rectal cancer (LARC) remains a matter of debate. This study evaluated the efficacy and safety of neoadjuvant FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, irinotecan) plus bevacizumab without radiotherapy in patients with magnetic resonance imaging-defined high-risk LARC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective, multicentre, single arm phase II trial was conducted in four Japanese Institutions between 2018 and 2024, enrolling patients with rectal adenocarcinoma and at least one high-risk criterion: clinical T4, lateral pelvic lymph node metastasis, mesorectal fascia involvement, or positive extramural vascular invasion. Patients received four cycles of FOLFOXIRI plus bevacizumab, followed by two cycles of FOLFOXIRI alone, before total mesorectal excision. The primary endpoint was pathological complete response (pCR); secondary endpoints included the R0 resection rate, local recurrence (LR), recurrence-free survival (RFS), overall survival (OS), and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>OF 50 eligible patients, 31 were enrolled before early trial closure due to a slow accrual (accrual rate 62%). All patients underwent surgery. The pCR rate was 10% (3 of 31) and R0 resection was achieved in 97% (30 of 31) of patients. The median follow-up was 36.7 months. The 3-year cumulative LR rate was 3%, with 3-year RFS and OS rates of 73 and 81%, respectively. Grade \u2265 3 neutropenia occurred in 29% of patients, with acceptable toxicity overall. No cases of gastrointestinal perforation were observed. Grade \u2265 III postoperative complications occurred in seven patients (23%), with the most frequent events being anastomotic leakage in two patients (7%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this phase II trial, although recruitment was suboptimal, neoadjuvant FOLFOXIRI plus bevacizumab achieved good local control without radiotherapy in patients with high-risk LARC. Although the pCR rate was modest compared with radiotherapy-based regimens, this chemotherapy-only approach may represent a reasonable option for select patients who are not suitable candidates for pelvic radiotherapy. Registration number: UMIN000037367 (https:\/\/www.umin.ac.jp\/english\/).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjsopen\/zraf163","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T12:53:16Z","timestamp":1764679996000},"source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant FOLFOXIRI plus bevacizumab without radiotherapy for high-risk rectal cancer: multicentre phase II trial"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-856X","authenticated-orcid":false,"given":"Takeru","family":"Matsuda","sequence":"first","affiliation":[{"name":"Division of Gastrointestinal Surgery, Department of Surgery, Kobe University Graduate School of Medicine , Kobe ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Nagatani","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Kobe University Graduate School of Medicine , Kobe ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7793-5013","authenticated-orcid":false,"given":"Yohei","family":"Funakoshi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Kobe University Graduate School of Medicine , Kobe ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Tsuboyama","sequence":"additional","affiliation":[{"name":"Department of Radiology, Kobe University Graduate School of Medicine , Kobe ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Mii","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kitaharima Medical Centre , Ono ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiko","family":"Kaneda","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kakogawa Central City Hospital , Kakogawa ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kakogawa Central City Hospital , Kakogawa ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Surgery, Department of Surgery, Kobe University Graduate School of Medicine , Kobe ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimihiro","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Surgery, Department of Surgery, Kobe University Graduate School of Medicine , Kobe ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8021-6116","authenticated-orcid":false,"given":"Naomi","family":"Kiyota","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Kobe University Graduate School of Medicine , Kobe ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironobu","family":"Minami","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Kobe University Graduate School of Medicine , Kobe ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Kakeji","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Surgery, Department of Surgery, Kobe University Graduate School of Medicine , Kobe ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"2026020910252259400_zraf163-B1","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1200\/JCO.2005.04.4875","article-title":"Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer","volume":"24","author":"Chau","year":"2006","journal-title":"J Clin Oncol"},{"issue":"(Suppl 4)","key":"2026020910252259400_zraf163-B2","doi-asserted-by":"crossref","first-page":"iv22","DOI":"10.1093\/annonc\/mdx224","article-title":"Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Glynne-Jones","year":"2017","journal-title":"Ann Oncol"},{"key":"2026020910252259400_zraf163-B3","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJMoa040694","article-title":"Preoperative versus postoperative chemoradiotherapy for rectal cancer","volume":"351","author":"Sauer","year":"2004","journal-title":"N Engl J Med"},{"key":"2026020910252259400_zraf163-B4","doi-asserted-by":"crossref","first-page":"874","DOI":"10.6004\/jnccn.2018.0061","article-title":"Rectal cancer, version 2.2018, NCCN clinical practice guidelines in oncology","volume":"16","author":"Benson","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"2026020910252259400_zraf163-B5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026020910252259400_zraf163-B6","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026020910252259400_zraf163-B7","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa2303269","article-title":"Preoperative treatment of locally advanced rectal cancer","volume":"389","author":"Schrag","year":"2023","journal-title":"N Engl J Med"},{"key":"2026020910252259400_zraf163-B8","doi-asserted-by":"crossref","first-page":"103703","DOI":"10.1016\/j.esmoop.2024.103703","article-title":"mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO\/ARO\/AIO 0214)","volume":"9","author":"Hofheinz","year":"2024","journal-title":"ESMO Open"},{"key":"2026020910252259400_zraf163-B9","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","article-title":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study","volume":"16","author":"Cremolini","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026020910252259400_zraf163-B10","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","article-title":"Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer","volume":"371","author":"Loupakis","year":"2014","journal-title":"N Engl J Med"},{"key":"2026020910252259400_zraf163-B11","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1200\/JGO.19.00367","article-title":"Treatment of patients with late-stage colorectal cancer: ASCO resource-stratified guideline","volume":"6","author":"Chiorean","year":"2020","journal-title":"JCO Glob Oncol"},{"key":"2026020910252259400_zraf163-B12","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"key":"2026020910252259400_zraf163-B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10147-019-01485-z","article-title":"Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer","volume":"25","author":"Hashiguchi","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"2026020910252259400_zraf163-B14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.23922\/jarc.2019-018","article-title":"Japanese classification of colorectal, appendiceal, and anal carcinoma: the 3d English edition [secondary publication]","volume":"3","author":"Japanese Society for Cancer of the Colon and Rectum","year":"2019","journal-title":"J Anus Rectum Colon"},{"key":"2026020910252259400_zraf163-B15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026020910252259400_zraf163-B16"},{"key":"2026020910252259400_zraf163-B17","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1200\/JCO.2016.66.6198","article-title":"Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase III trial","volume":"34","author":"Deng","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026020910252259400_zraf163-B18","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/jjco\/hyt115","article-title":"Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 phase II trial","volume":"43","author":"Uehara","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"2026020910252259400_zraf163-B19","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/SLA.0000000000005780","article-title":"Neoadjuvant chemotherapy with CAPOX versus chemoradiation for locally advanced rectal cancer with uninvolved mesorectal fascia (CONVERT): initial results of a phase III trial","volume":"277","author":"Mei","year":"2023","journal-title":"Ann Surg"},{"key":"2026020910252259400_zraf163-B20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/cas.12041","article-title":"Phase II study of preoperative chemoradiation with S-1 plus oxaliplatin in patients with locally advanced rectal cancer","volume":"104","author":"Lee","year":"2013","journal-title":"Cancer Sci"},{"key":"2026020910252259400_zraf163-B21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"2026020910252259400_zraf163-B22","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1200\/JCO.21.01667","article-title":"Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR)","volume":"40","author":"Jin","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026020910252259400_zraf163-B23","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1097\/SLA.0000000000005799","article-title":"Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial","volume":"278","author":"Dijkstra","year":"2023","journal-title":"Ann Surg"},{"key":"2026020910252259400_zraf163-B24","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1001\/jamaoncol.2019.2294","article-title":"Effect of aflibercept plus modified FOLFOX6 induction chemotherapy before standard chemoradiotherapy and surgery in patients with high-risk rectal adenocarcinoma: the GEMCAD 1402 randomized clinical trial","volume":"5","author":"Fern\u00e1ndez-Martos","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026020910252259400_zraf163-B25","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/jnci\/djad120","article-title":"Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402","volume":"115","author":"Pes\u00e1ntez","year":"2023","journal-title":"J Natl Cancer Inst"}],"container-title":["BJS Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjsopen\/article-pdf\/10\/1\/zraf163\/66820620\/zraf163.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjsopen\/article-pdf\/10\/1\/zraf163\/66820620\/zraf163.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T15:25:31Z","timestamp":1770650731000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjsopen\/article\/doi\/10.1093\/bjsopen\/zraf163\/8469381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,29]]}},"URL":"https:\/\/doi.org\/10.1093\/bjsopen\/zraf163","relation":{},"ISSN":["2474-9842"],"issn-type":[{"value":"2474-9842","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,12,29]]},"article-number":"zraf163"}}